Additionally, immunosuppressive regimens involving thiopurines, either independently or in conjunction with anti-TNF-alpha agents, can cause leukocytosis, thrombocytopenia and, in prolonged scenarios, the emergence of acute myeloid leukemia and severe myelodysplastic syndromes (MDS) as adverse outcomes [3,5]. This evidence concerns the gene TNF and myelodysplastic syndrome.